Roche’s Giredestrant NDA Accepted by FDA for Early Breast Cancer
BASEL, Switzerland, June 2, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
Roche
Advertisement
FDA Accepts Genentech NDA for Giredestrant in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif., June 1, 2026 Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted...
Roche Highlights Promising Obesity Pipeline Data Ahead of ADA 2026
Basel, Switzerland, June 1, 2026 Roche announced that new clinical data from its obesity portfolio will be presented at...
Genentech Advances Obesity Portfolio with New ADA 2026 Data
SOUTH SAN FRANCISCO, Calif., May 31, 2026 Genentech, a member of the Roche Group, announced that new clinical data...
Roche Launches AI-Powered Liver Disease Panel for Early Detection
BASEL, Switzerland, May 27, 2026 Roche has announced the launch of its groundbreaking Liver Disease Panel, the healthcare industry’s...
Advertisements
Genentech Highlights Giredestrant Data at ASCO 2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 Genentech, a member of the Roche Group, announced that it will present...
Roche Gains CE Mark Approval for Elecsys pTau217 Test
BASEL, Switzerland, May 12, 2026 Roche announced that it has received European CE Mark approval for Elecsys® plasma phosphorylated-tau...
Roche to Acquire PathAI in $1.05 Billion AI Diagnostics Deal
BASEL, Switzerland – May 7, 2026 Roche announced it has entered into a definitive merger agreement to acquire PathAI,...
Roche ENSPRYNG Shows MOGAD Clinical Benefit Data
BASEL, Switzerland, April 2026 Roche reported new clinical findings demonstrating the effectiveness of ENSPRYNG® (satralizumab) in reducing relapse risk...
Roche Gets CE Mark for Elecsys NfL MS Blood Test
BASEL, Switzerland, April 13, 2026 Roche has announced that its Elecsys® Neurofilament Light Chain (NfL) blood test has received...
Advertisement
